Haemonetics Stock Today
| HAE Stock | USD 57.77 1.69 2.84% |
PerformanceWeakest
| Odds Of DistressTiny
|
Haemonetics is trading at 57.77 as of the 11th of February 2026, a 2.84% down since the beginning of the trading day. The stock's lowest day price was 57.77. Haemonetics has under 5 % chance of experiencing financial distress over the next 2 years, but has generated negative returns over the last 90 days. Note, on May 25, 2021, Representative Lois Frankel of US Congress acquired under $15k worth of Haemonetics's common stock.
Business Domain Health Care Equipment & Services | IPO Date 9th of May 1991 | Category Healthcare | Classification Health Care |
Haemonetics Corporation, a healthcare company, provides medical products and solutions. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts. Haemonetics Corp operates under Medical Instruments Supplies classification in the United States and is traded on New York Stock Exchange. The company has 46.47 M outstanding shares of which 3.08 M shares are currently shorted by investors with about 4.6 days to cover. More on Haemonetics
Moving together with Haemonetics Stock
| 0.75 | 2DR | Inspire Medical Systems Earnings Call Today | PairCorr |
Moving against Haemonetics Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Haemonetics Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO | Christopher Simon | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Ideas | (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Old Names | [HAEMATO, HAEMATO, HAEMATO AG, HAEMATO AG] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Health Care Equipment & Supplies, Health Care Equipment & Services, Health Care, NYSE Composite, SP Midcap 400, Obamacare Repeal, Baby Boomer Prospects, Health Care, Health Care Equipment & Supplies, Medical Instruments & Supplies, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsBy employing borrowed capital, Haemonetics can potentially magnify investment returns. Examining the debt-to-assets ratio offers investors perspective on Haemonetics' use of financial leverage and reveals what portion of Haemonetics' asset base relies on creditor financing.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Haemonetics (HAE) is traded on New York Stock Exchange in USA and employs 3,023 people. Haemonetics is listed under Health Care Equipment & Supplies category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a total capitalization of 2.7 B. Haemonetics runs under Health Care Equipment & Supplies sector within Health Care industry. The entity has 46.47 M outstanding shares of which 3.08 M shares are currently shorted by investors with about 4.6 days to cover.
Haemonetics has about 306.76 M in cash with 181.72 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.79.
Check Haemonetics Probability Of Bankruptcy
Ownership AllocationThe majority of Haemonetics outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Haemonetics to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Haemonetics. Please pay attention to any change in the institutional holdings of Haemonetics as this could imply that something significant has changed or is about to change at the company. Please note that on May 25, 2021, Representative Lois Frankel of US Congress acquired under $15k worth of Haemonetics's common stock.
Check Haemonetics Ownership Details
Haemonetics Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Btim Corp | 2025-06-30 | 1.1 M | |
| Dimensional Fund Advisors, Inc. | 2025-06-30 | 1.1 M | |
| Allspring Global Investments Holdings, Llc | 2025-06-30 | 949.5 K | |
| Sg Capital Management, Llc | 2025-06-30 | 906.9 K | |
| Schroder Investment Management Group | 2025-06-30 | 892.4 K | |
| Ubs Group Ag | 2025-06-30 | 869.8 K | |
| Fmr Inc | 2025-06-30 | 835.8 K | |
| Victory Capital Management Inc. | 2025-06-30 | 778.8 K | |
| Fisher Asset Management, Llc | 2025-06-30 | 689.1 K | |
| Blackrock Inc | 2025-06-30 | 6.4 M | |
| Vanguard Group Inc | 2025-06-30 | 5 M |
Haemonetics Historical Income Statement
Haemonetics Stock Against Markets
Haemonetics Corporate Directors
| Robert Abernathy | Independent Director | Profile | |
| Claire Pomeroy | Independent Director | Profile | |
| Catherine Burzik | Independent Director | Profile | |
| Mark Kroll | Independent Director | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Haemonetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Will Health Care Equipment & Supplies sector continue expanding? Could Haemonetics diversify its offerings? Factors like these will boost the valuation of Haemonetics. Market participants price Haemonetics higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Haemonetics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 0.284 | Earnings Share 3.63 | Revenue Per Share | Quarterly Revenue Growth (0.03) | Return On Assets |
The market value of Haemonetics is measured differently than its book value, which is the value of Haemonetics that is recorded on the company's balance sheet. Investors also form their own opinion of Haemonetics' value that differs from its market value or its book value, called intrinsic value, which is Haemonetics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Haemonetics' market value can be influenced by many factors that don't directly affect Haemonetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Haemonetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Haemonetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, Haemonetics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.